一线纳武利尤单抗联合伊匹木单抗治疗晚期非小细胞肺癌的长期生存:汇总分析
该汇总分析纳入四项一线纳武利尤单抗联合伊匹木单抗治疗晚期非小细胞肺癌研究的数据(N=1332),最短随访29.1-58.9个月。中位总生存期18.6个月,3年总生存率35%;客观缓解率36%,中位缓解持续时间23.7个月。6个月时缓解者的3年总生存率为66%,高于疾病稳定者的22%和疾病进展者的14%。
要点
- 汇总人群中位总生存期18.6个月,3年总生存率35%,中位无进展生存期5.4个月。
- 肿瘤PD-L1≥50%者3年总生存率48%,PD-L1<1%者为30%。
- 6个月时缓解者3年总生存率66%,疾病稳定者22%,疾病进展者14%。
核心结论
- 在一线纳武利尤单抗联合伊匹木单抗治疗晚期非小细胞肺癌的大规模人群中,长期生存获益和持久缓解进一步支持该方案作为一线治疗选择。
研究设计与样本
- 汇总四项一线纳武利尤单抗联合伊匹木单抗治疗晚期非小细胞肺癌研究的数据(CheckMate 227 Part 1、817 cohort A、568 Part 1和012),汇总人群N=1332,最短随访29.1-58.9个月。
- 评估总生存期、无进展生存期、客观缓解率、缓解持续时间及安全性,并按6个月时缓解状态和缓解者肿瘤负荷缩小程度进行里程碑分析。
主要发现
- 汇总人群中位总生存期为18.6个月,3年总生存率为35%;中位无进展生存期为5.4个月,3年无进展生存率为17%。
- 客观缓解率为36%,中位缓解持续时间为23.7个月,38%的缓解者在3年时仍持续缓解。
- 肿瘤PD-L1<1%、≥1%、1%-49%、≥50%者的3年总生存率分别为30%、38%、30%、48%。
- 鳞癌和非鳞癌患者的3年总生存率分别为30%和38%。
- 6个月时缓解者、疾病稳定者和疾病进展者的3年总生存率分别为66%、22%和14%;肿瘤负荷缩小≥80%、50%至<80%、30%至<50%者的3年总生存率分别为85%、72%和44%。
关键数值与推荐
- 年龄≥75岁患者的疗效结局与总体汇总人群相似(中位总生存期20.1个月,3年总生存率34%)。
- 汇总人群中未发现新的安全性信号。
临床怎么用
- 原文结论认为长期生存获益和持久缓解进一步支持该方案作为晚期非小细胞肺癌的一线治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: First-line nivolumab plus ipilimumab prolongs survival versus chemotherapy in advanced non-small-cell lung cancer (NSCLC). We further characterized clinical benefit with this regimen in a large pooled patient population and assessed the effect of response on survival. PATIENTS AND METHODS: Data were pooled from four studies of first-line nivolumab plus ipilimumab in advanced NSCLC (CheckMate 227 Part 1, 817 cohort A, 568 Part 1, and 012). Overall survival (OS), progression-free survival (PFS), objective response rate, duration of response, and safety were assessed. Landmark analyses of OS by response status at 6 months and by tumor burden reduction in responders to nivolumab plus ipilimumab were also assessed. RESULTS: In the pooled population (N = 1332) with a minimum follow-up of 29.1-58.9 months, median OS was 18.6 months, with a 3-year OS rate of 35%; median PFS was 5.4 months (3-year PFS rate, 17%). Objective response rate was 36%; median duration of response was 23.7 months, with 38% of responders having an ongoing response at 3 years. In patients with tumor programmed death-ligand 1 (PD-L1) <1%, ≥1%, 1%-49%, or ≥50%, 3-year OS rates were 30%, 38%, 30%, and 48%. Three-year OS rates were 30% and 38% in patients with squamous or non-squamous histology. Efficacy outcomes in patients aged ≥75 years were similar to the overall pooled population (median OS, 20.1 months; 3-year OS rate, 34%). In the pooled population, responders to nivolumab plus ipilimumab at 6 months had longer post-landmark OS than those with stable or progressive disease; 3-year OS rates were 66%, 22%, and 14%, respectively. Greater depth of response was associated with prolonged survival; in patients with tumor burden reduction ≥80%, 50% to <80%, or 30% to <50%, 3-year OS rates were 85%, 72%, and 44%, respectively. No new safety signals were identified in the pooled population. CONCLUSION: Long-term survival benefit and durable response with nivolumab plus ipilimumab in this large patient population further support this first-line treatment option for advanced NSCLC.
引用
- Borghaei H, Ciuleanu TE, Lee JS, et al. Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis. Ann Oncol. 2022. PMID: 36414192. doi:10.1016/j.annonc.2022.11.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。